--News Direct--
Amplia Therapeutics Ltd (ASX:ATX) CEO Dr Chris Burns tells Proactive the company has received grant funding to undertake a research collaboration with Australia’s national science agency to develop topical formulations of its FAK inhibitors. Amplia will work with researchers at CSIRO to help develop formulations that could be applied topically to wounds and burns to aid healing and reduce scarring.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
jonathan@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/amplia-secures-funding-to-assess-amp945-topical-applications-200112584
